Stéphane Delahaye

586 total citations
23 papers, 414 citations indexed

About

Stéphane Delahaye is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Stéphane Delahaye has authored 23 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Cardiology and Cardiovascular Medicine and 5 papers in Oncology. Recurrent topics in Stéphane Delahaye's work include Drug Transport and Resistance Mechanisms (5 papers), Receptor Mechanisms and Signaling (4 papers) and Renin-Angiotensin System Studies (4 papers). Stéphane Delahaye is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Receptor Mechanisms and Signaling (4 papers) and Renin-Angiotensin System Studies (4 papers). Stéphane Delahaye collaborates with scholars based in Switzerland, Belgium and Denmark. Stéphane Delahaye's co-authors include Alexander Treiber, Martine Clozel, Roger Schneiter, Patrick Hess, Ruben de Kanter, Claude Ecoffey, Pascal Le Corre, Jean-Pierre Estèbe, Gilles Dollo and F. Chevanne and has published in prestigious journals such as PLoS ONE, Langmuir and Journal of Medicinal Chemistry.

In The Last Decade

Stéphane Delahaye

22 papers receiving 395 citations

Peers

Countries citing papers authored by Stéphane Delahaye

Since Specialization

Citations

This map shows the geographic impact of Stéphane Delahaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Delahaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Delahaye more than expected).

Fields of papers citing papers by Stéphane Delahaye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Delahaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Delahaye. The network helps show where Stéphane Delahaye may publish in the future.

Co-authorship network of co-authors of Stéphane Delahaye

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Delahaye. A scholar is included among the top collaborators of Stéphane Delahaye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Delahaye. Stéphane Delahaye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold 2024 ·Journal of Medicinal Chemistry ·Cyrille Lescop, Christine Brotschi, (unknown), Christoph P. Sager, Magdalena Birker, Keith Morrison, Sylvie Froidevaux, Stéphane Delahaye, Oliver Nayler, Martin H. Bolli	2
2	Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity 2024 ·Journal of Medicinal Chemistry ·(unknown), Dorte Renneberg, (unknown), (unknown), Kurt Hilpert, (unknown), Stéphane Delahaye, (unknown), Mark Murphy	0
3	Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo 2023 ·Clinical and Translational Science ·(unknown), Jasper Dingemanse, Stéphane Delahaye, Luboš Janů, John van den Anker, Benjamin Berger, Priska Kaufmann	2
4	CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4‐Hydroxypiperidinol Metabolites 2023 ·ChemMedChem ·Alexander Treiber, Hamed Aissaoui, Stéphane Delahaye, (unknown), (unknown), (unknown), (unknown), (unknown), Christoph Boss	5
5	The metabolism of the dual orexin receptor antagonist daridorexant 2023 ·Xenobiotica ·Alexander Treiber, Stéphane Delahaye, (unknown), (unknown), John Gatfield, (unknown)	2
6	Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel 2022 ·Clinical and Translational Science ·(unknown), (unknown), Stéphane Delahaye, Andreas Krause, (unknown), Atef Halabi, Jasper Dingemanse	4
7	Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist 2021 ·Clinical Pharmacokinetics ·Benjamin Berger, Jasper Dingemanse, (unknown), Stéphane Delahaye, Urs Duthaler, Clemens Muehlan, Stephan Krähenbühl	17
8	The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern 2020 ·Pharmacology Research & Perspectives ·Alexander Treiber, Stéphane Delahaye, (unknown), Carmela Gnerre	3
9	Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension 2019 ·Journal of Pharmacology and Experimental Therapeutics ·F. Trensz, (unknown), (unknown), (unknown), (unknown), Markus Rey, Daniel S. Strasser, Stéphane Delahaye, Patrick Hess, Enrico Vezzali, (unknown), Joël Ménard, Martine Clozel, Marc Iglarz	42
10	The metabolism and drug–drug interaction potential of the selective prostacyclin receptor agonist selexipag 2017 ·Xenobiotica ·Carmela Gnerre, (unknown), (unknown), Päivi Äänismaa, Thomas Pfeifer, Stéphane Delahaye, Ruben de Kanter, Tomohiko Ichikawa, Tetsuhiro Yamada, Alexander Treiber	14
11	Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers 2015 ·Bioorganic & Medicinal Chemistry Letters ·Dorte Renneberg, (unknown), Markus Rey, Patrick Hess, Stéphane Delahaye, John Gatfield, Marc Iglarz, Kurt Hilpert	4
12	Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions 2015 ·Clinical Pharmacokinetics ·Ruben de Kanter, Patricia N. Sidharta, Stéphane Delahaye, Carmela Gnerre, (unknown), Stephan Buchmann, Christopher Kohl, Alexander Treiber	25
13	Macitentan Does Not Interfere with Hepatic Bile Salt Transport 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Alexander Treiber, Päivi Äänismaa, Ruben de Kanter, Stéphane Delahaye, (unknown), Patrick Hess, Patricia N. Sidharta	33
14	Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P1 Receptor Modulator 2013 ·PLoS ONE ·Markus Rey, Patrick Hess, Martine Clozel, Stéphane Delahaye, John Gatfield, Oliver Nayler, Beat Steiner	14
15	Identification of a New Chemical Class of Antimalarials 2012 ·The Journal of Infectious Diseases ·(unknown), Hamed Aissaoui, Christoph Boss, Zbynek Bozdech, Reto Brun, Olivier Corminboeuf, Stéphane Delahaye, Christoph Fischli, (unknown), Marcel Kaiser, (unknown), Solange Meyer, Petros Papastogiannidis, Romain Siegrist, Till S. Voss, Richard W.D. Welford, Sergio Wittlin, Christoph A. Binkert	25
16	New classes of potent and bioavailable human renin inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Sylvia Richard‐Bildstein, Daniel Bur, Lars Prade, Olivier Corminboeuf, Christoph Boss, Corinna Grisostomi, Thierry Sifferlen, (unknown), Patrick Hess, Stéphane Delahaye, Alexander Treiber, Thomas Weller, Christoph A. Binkert, Beat Steiner, Walter Fischli	15
17	Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin Inhibitors 2009 ·Journal of Medicinal Chemistry ·(unknown), Daniel Bur, Thomas Weller, Sylvia Richard‐Bildstein, (unknown), Thierry Sifferlen, Olivier Corminboeuf, Corinna Grisostomi, Christoph Boss, Lars Prade, Stéphane Delahaye, Alexander Treiber, (unknown), Christoph A. Binkert, Patrick Hess, Beat Steiner, Walter Fischli	44
18	Alkalinization of intra-cuff lidocaine and use of gel lubrication protect against tracheal tube-induced emergence phenomena 2004 ·British Journal of Anaesthesia ·Jean-Pierre Estèbe, Stéphane Delahaye, Pascal Le Corre, Gilles Dollo, Alain Le Naoures, F. Chevanne, Claude Ecoffey	59
19	Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Alexander Treiber, Roger Schneiter, Stéphane Delahaye, Martine Clozel	71
20	No influence of the endothelin receptor antagonist bosentan on basal and indomethacin‐induced reduction of cerebral blood flow in pigs 2003 ·Acta Anaesthesiologica Scandinavica ·Mads Rasmussen, (unknown), Alexander Treiber, Stéphane Delahaye, (unknown), (unknown), Kate E. Therkelsen, Albert Gjedde, Jens Astrup	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact